Global variations in the incidence of prostate cancer are probably partly associated with differential risk profiles, but differences in use of PSA testing and levels of awareness of potential signs and symptoms of prostate cancer are also important contributory factors. This evidence concerns the gene KLK3 and prostate carcinoma.